Clotting Predisposition in Carcinoma of the Prostate

Dobbs, Robert M.; Barber, Judy A.; Weigel, John W.; Bergin, James E.

doi:10.1016/s0022-5347(17)56097-8

Cited by 29 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coagulation abnormalities in cancer patients are well documented, and a hypercoagulable state leading to vascular thrombosis has been reported (Miller et al, 1967;Davis et al, 1969). Attempts have been made to study coagulation abnormalities following various therapeutic modalities in various cancers, particularly with reference to chemotherapy (Hicsonmez and Buyukpamukcu, 1977;Dobbs et al, 1980;Enck and Rias 1984;Goodnough et al, 1984). The influence of cytotoxic agents on coagulation factors and platelet function has not so far been well defined, and published data are conflicting (Canobbio et al, 1986).…”

mentioning

confidence: 99%

Combination chemotherapy for breast carcinoma using a combination of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF) causes a platelet aggregation defect

Kumar¹,

Chaturvedi²,

Gupta³

1996

Int. J. Cancer

View full text Add to dashboard Cite

Various coagulation parameters including platelet aggregation were evaluated during the course of treatment in 25 patients with breast carcinoma receiving a combination of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF). No significant changes were found in whole blood clotting time (WBCT), prothrombin time (PT), kaolin cephalin clotting time (KCCT), platelet count (PC) and prothrombin consumption index (PCI). The CMF combination induced a significant reduction in platelet factor‐3 (PF3) availability and reduction in platelet aggregation to ADP and adrenaline. These defects occurred without development of thrombocytopenia. The changes occurred on the 8th day of chemotherapy and a progressive suppression in platelet aggregation was noted during subsequent follow‐up. This acquired abnormality in platelet aggregation and PF3 availability may be responsible for various hemorrhagic manifestations such as mucositis, epistaxis and hemorrhagic cystitis following CMF therapy. Further, these changes precede the onset of life‐threatening complication of thrombocytopenia. The study of platelet aggregation should be considered besides platelet counting in patients on CMF combination to assess bleeding diathesis. © 1996 Wiley‐Liss, Inc.

show abstract

mentioning

confidence: 99%

Combination chemotherapy for breast carcinoma using a combination of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF) causes a platelet aggregation defect

Kumar¹,

Chaturvedi²,

Gupta³

1996

Int. J. Cancer

View full text Add to dashboard Cite

show abstract

“…In a recent study (Dobbs, Barber, Weigel & Bergin, 1980) a correlation between advanced stages of prostatic cancer and depression of serum antithrombin 111 activity was demonstrated. The addition of estrogens resulted in a further depression of antithrombin 111.…”

Section: Discussionmentioning

confidence: 96%

Cisobitan® in Treatment of Prostatic Cancer

Alfthan

Andersson

et al. 1983

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

Cisobitan, an organosilicon compound with estrogenic and antigonadotropic properties has been evaluated clinically in comparison with an estrogen preparation. In a multicenter study a total of 140 patients with well and moderately well differentiated prostatic cancer were randomly allocated to treatment with Cisobitan or Estradurin/Etivex, 70 to each group. Of 34 patients with poorly differentiated prostatic cancer 18 were given Cisobitan--and 16 were given Estracyt-treatment. Among the patients with well and moderately well differentiated prostatic cancer there were, disregarding mortality, no major differences in subjective, objective or laboratory response to the two kinds of treatment. The pattern of side effects was similar, but oedema requiring diuretics occurred more often in the estrogen treated group. There was a significant difference in mortality at 12 months between the groups, two in the Cisobitan group and ten in the estrogen treated group. Cancer was the cause of death in two patients in the estrogen treated group. All other patients succumbed in cardiovascular diseases. At 24 months the difference in mortality rate was less pronounced: Another ten patients had died in the Cisobitan treated group and seven among the estrogen treated patients. Cancer was responsible for the deaths in seven of the Cisobitan patients compared to four of the estrogen treated patients. Within three years one more patient in both groups had died. Of the 34 patients with poorly differentiated cancer, twelve were alive at the 24 months' follow up, six in the Cisobitan group and six in the Estracyt group.

show abstract

“…DES also decreases fibrinolysis by reducing levels of plasminogen activator [49]. It has also been noted that another important factor in the coagulation cascade, antithrombin III, is significantly decreased with oestrogen administration [50,51]. Other proposed mechanisms through which oestrogens contribute to cardiovascular complications include alterations in platelet function and serum lipid profiles [52,53].…”

Section: Mechanism Of Oestrogen Side-effectsmentioning

confidence: 99%

Diethylstilboestrol for the treatment of prostate cancer: past, present and future

Turo¹,

Smolski²,

Esler³

et al. 2013

Scandinavian Journal of Urology

View full text Add to dashboard Cite

The aim of this review was to discuss the most recent data from current trials of diethylstilboestrol (DES) to identify its present role in advanced prostate cancer treatment as new hormonal therapies emerge. The most relevant clinical studies using DES in castration-refractory prostate cancer (CRPC) were identified from the literature. The safety, efficacy, outcomes and mechanisms of action are summarized. In the age of chemotherapy this review highlights the efficacy of oestrogen therapy in CRPC. The optimal point in the therapeutic pathway at which DES should be prescribed remains to be established.

show abstract

Clotting Predisposition in Carcinoma of the Prostate

Cited by 29 publications

References 8 publications

Combination chemotherapy for breast carcinoma using a combination of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF) causes a platelet aggregation defect

Combination chemotherapy for breast carcinoma using a combination of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF) causes a platelet aggregation defect

Cisobitan® in Treatment of Prostatic Cancer

Diethylstilboestrol for the treatment of prostate cancer: past, present and future

Contact Info

Product

Resources

About